Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Fecal Blood Test Defines Risk of Colorectal Cancer

By LabMedica International staff writers
Posted on 01 Jun 2011
Immunochemical fecal occult blood testing (iFOBT), uses antibodies to detect hidden human hemoglobin in stool, and is widely used to screen for colorectal cancer. More...


Individuals with fecal hemoglobin concentrations higher than 100 ng/mL are at increased risk of colorectal neoplasia, but little is known about the subsequent risk of developing colorectal neoplasia for people who have a negative result.

A team from the National Taiwan University (Taipei, Taiwan) examined 44,324 participants from a community-based iFOBT screening program for residents aged 40-69 years, between 2001 and 2007. The participants who had negative results at the first screen were followed up to find cases of colorectal neoplasia. Modeling was used to calculate the risk of developing neoplasia after controlling for conventional risk factors including age, sex, family history of colorectal cancer, consumption of meat, and body mass index. They also calculated the subsequent risk for nonreferrals, individuals with fecal hemoglobin concentrations higher than 100 ng/mL who refused colonoscopy, and false positives, in whom colonoscopy did not find disease.

Among individuals with negative results, hemoglobin concentration was predictive of neoplasia and subsequent progression to cancer. The median follow-up was 4.39 years for all participants, during which the incidence of colorectal neoplasia increased from 1.74/1,000 person-years for those with baseline fecal hemoglobin concentration 1 ng/mL - 19 ng/mL, to 7.08/1,000 person-years for those with a baseline concentration of 80 ng/mL - 99 ng/mL. The higher the initial fecal hemoglobin concentration was, the greater the likelihood there was of developing colorectal neoplasia. Nonreferrals had the highest risk of colorectal neoplasia and false-positive cases the lowest risk.

The fecal hemoglobin was measured using the OC-Sensor iFOBT kits manufactured by Eiken Chemical Co. (Tokyo, Japan). The authors suggest that fecal hemoglobin could be used to define groups at low, intermediate, and high risk and tailor screening strategies accordingly. Callum G. Fraser, PhD, a professor at the University of Dundee, (UK), commenting on the study said, "There is likely a continuum of risk of colorectal neoplasia as fecal hemoglobin increases from zero. These findings have important implications for the design of future screening programs." The study was published on May 16, 2011, in Lancet Oncology.

Related Links:
National Taiwan University
Eiken Chemical Co.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.